Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MDH1 | P40925 | 2/20 | 0.49 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628473 | 0.99 | MAPT (0.49) | MAPTSMN1; SMN2MDH1RARBCYP4A11 | |
| SCHEMBL21628713 | 0.97 | MDH1 (0.48) | MAPTSMN1; SMN2MDH1RARBCYP4A11 | |
| SCHEMBL21628424 | 0.92 | VNN1 (0.42) | MAPTSMN1; SMN2MDH1CYP4A11 | |
| SCHEMBL21628741 | 0.90 | PLA2G4A (0.45) | MAPTSMN1; SMN2MDH1RARBTHRB | |
| SCHEMBL21628399 | 0.89 | PLA2G4A (0.46) | RARBTHRBRARARARG | |
| SCHEMBL21628886 | 0.89 | RARB (0.53) | MAPTSMN1; SMN2RARBRARARARG | |
| SCHEMBL21628482 | 0.88 | VNN1 (0.44) | MAPTSMN1; SMN2 | |
| SCHEMBL21628883 | 0.88 | SMPD1 (0.52) | RARBSMPD1 | |
| SCHEMBL21628857 | 0.88 | PLK1 (0.49) | MAPTSMN1; SMN2RARBPLK1PLK3 | |
| SCHEMBL29921175 | 0.88 | PLK1 (0.49) | MAPTSMN1; SMN2RARBPLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | disclosed |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-12-21 | — | — | US | disclosed |
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | MAPT 2272/4885SMN1; SMN2 796/4885MDH1 1376/4885 |
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | MAPT 2272/4885SMN1; SMN2 796/4885MDH1 1376/4885 |
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | MAPT 2195/4885SMN1; SMN2 1107/4885MDH1 1290/4885 |
| US-12600696-B2 | Aromatic compounds | CCR1, CCRL2, AHR | MAPT 4404/4885SMN1; SMN2 919/4885MDH1 2247/4885 |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | MAPT 2272/4885SMN1; SMN2 796/4885MDH1 1376/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | MAPT 2272/4885SMN1; SMN2 796/4885MDH1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.